Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ocumension Therapeutics ( (HK:1477) ) has shared an announcement.
Ocumension Therapeutics reported a sharp acceleration in growth for 2025, with revenue surging 92.7% year on year to RMB804.4 million and a comprehensive gross margin of 44.9%, driven mainly by strong sales of ophthalmic products including Xalatan, Azep and assets acquired from Alcon, as well as higher sales-based royalties from the commercialization of Boyoujing. Adjusted net loss narrowed by 51.1% to RMB89.9 million and adjusted EBITDA turned positive at RMB50.3 million, reflecting operating efficiency gains and signaling a key milestone on the path toward sustained profitability.
Operationally, the company consolidated its position in the ophthalmic market as core product Youshiying continued steady sales growth, while Boyoujing gained marketing approval in China for wet age-related macular degeneration and diabetic macular edema, strengthening its fundus disease franchise. R&D momentum was underscored by phase II data for the self-developed dry eye candidate OT-202 being published in the leading journal Ophthalmology, and manufacturing scale-up at the Suzhou site, including planned localization of Youshiying production in 2026, is expected to lower costs and support higher commercial volumes.
The most recent analyst rating on (HK:1477) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on Ocumension Therapeutics stock, see the HK:1477 Stock Forecast page.
More about Ocumension Therapeutics
Ocumension Therapeutics is a Cayman Islands–incorporated biopharmaceutical company focused on ophthalmology, developing and commercializing treatments for eye diseases in China and globally. Its portfolio includes in-licensed and self-developed products such as intravitreal implants and injections targeting conditions like age-related macular degeneration, diabetic macular edema and dry eye disease, complemented by expanded in-hospital market coverage and growing manufacturing capabilities.
Average Trading Volume: 1,075,333
Technical Sentiment Signal: Sell
Current Market Cap: HK$5.73B
Learn more about 1477 stock on TipRanks’ Stock Analysis page.